Skip to content
Medical Health Aged Care, Transport Automotive

Setting new standards for healthcare: DB Schenker secures Good Distribution Practice (GDP) certification for more than 150 stations

DB SCHENKER Australia and New Zealand 2 mins read

DB Schenker continues to solidify its commitment to excellence and regulatory compliance in pharmaceutical supply chains by achieving certifications in accordance with Good Distribution Practice (GDP) standards for 157 of its stations, including those in Sydney, Melbourne, and Auckland.

The most important markets for the global trade of medical goods, spanning the Americas, Europe, and Asia, are now covered within the DB SCHENKER life+ product portfolio. Stations here refer to operational units at DB Schenker.

By achieving this milestone, DB Schenker can now cover 80% of the world's healthcare flows with their recent certificates, making it one of the world’s largest GDP-compliant logistics networks. DB Schenker can now even better meet the evolving needs of the global pharmaceutical industry.

Healthcare is a highly regulated industry governed by various guidelines, making GDP compliance critical. With Good Distribution Practice, DB Schenker follows a quality guideline that ensures that the integrity and quality of pharmaceutical products is maintained throughout the entire supply chain process.

DB Schenker’s internal Global Healthcare Quality Management System addresses the Good Distribution Practices for medicinal products for human and veterinary use and related active substances set out by the European Union (EU) and the World Health Organisation (WHO). DB Schenker ensures these requirements are complied with through the internal Directive Healthcare Quality Management, which forms the basis of DB SCHENKER life+.

Veronique Dameme, Head of Global Vertical Market Healthcare at DB Schenker: “At the end of every healthcare supply chain there is a patient. That’s why we ensure that medical products are stored and distributed in accordance with the highest standards. The successful GDP certification of our facilities marks a significant milestone on our roadmap and shows our ongoing pursuit of excellence in pharmaceutical logistics.”

When DB Schenker started the implementation process for certification, the first goal was to define a global standard valid for all transport modes. This made the GDP certificate suitable. The comprehensive certification ensures that the process, infrastructure, and staffing comply with the stringent requirements of the pharmaceutical industry, using this ideal approach across all business units. After a station is awarded certification following successful completion of an internal certification process, a risk-based re-audit is performed based on continuously measured KPIs. This is repeated at least every three years to ensure the highest quality is maintained.

DB Schenker continuously analyses its customers' need for additional locations. Within the next twelve months, the global logistics service provider plans to certify over 180 of its stations to be able to organise and manage GDP-compliant logistics.


About us:

About DB Schenker 
With around 76,600 employees at more than 1,850 locations in over 130 countries, DB Schenker is one of the world’s leading logistics service providers. The company operates land, air, and ocean transportation services, and it also offers comprehensive logistics and global supply chain management solutions from a single source. Aiming for a sustainable future of the logistics industry, DB Schenker continuously invests in innovative transport solutions, renewable energies, and low-emission products for its customers.  
www.dbschenker.com

Blog.dbschenker.com


Contact details:

Jack Mallen-Cooper
PR Consultant
Whyte Public Relations
(02) 9901 4306
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 16/03/2026
  • 10:41
Samsung Bioepis Co., Ltd.

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO’s proprietary microsphere technology Epis NexLab, a…

  • Contains:
  • Medical Health Aged Care
  • 16/03/2026
  • 10:00
Dementia Australia

Dementia carers funding commitment welcomed

Dementia Australia welcomes theSouth Australian Labor Party’s electioncommitmentto fund the delivery of a Dementia Carers Wellbeing and Education Programand calls upon all South Australian parties and independents to offer bi-partisan support. Dementia Australia CEO Professor TanyaBuchanansaid the 12-month South Australian program would support unpaid carers with evidence-based wellbeing and education interventions, aimed at improving carer health, reducing stress and strengthening carers capacity to sustain their caring role. “With dementia now the leading cause of death for Australians, and with an estimated 35,800 people living with all forms of dementia in South Australia, support for carers is vital,” Professor Buchanan said.…

  • Contains:
  • Medical Health Aged Care
  • 16/03/2026
  • 09:44
Children's Cancer CoLab

Surviving childhood cancer is not enough – 20+ national organisations call for lifelong support for survivors

Key Facts: Around 20,000 Australians are living with lifelong effects of childhood and adolescent cancer, with numbers expected to grow 20% in the next decade Eight in 10 childhood cancer survivors experience at least one long-term health problem, with mortality rates up to 10 times higher than their peers Current survivorship care plans are often limited to clinical perspectives and lack holistic, whole-family support More than 21 organisations have united to demand lifelong, comprehensive care for childhood cancer survivors through a nationally endorsed position statement National health, research and advocacy organisations have united to demand lifelong care for childhood and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.